Skip to main content
Premium Trial:

Request an Annual Quote

DOWNLOADS & UPGRADES: Embreo, LabImage, PhyloGrapher, HOBACGEN


Peter Tribble of the UK’s Human Genome Mapping Project Computing Services has released Embreo, a toolkit for building clients that can execute applications and access data held on servers. It is available at


Kapelan, a Halle, Germany-based subsidiary of Labsoft Diagnostics, has launched a new version of its gel analysis software LabImage at


Alexander Kozik of the University of California, Davis, has released PhyloGrapher, a visualization tool for studying evolutionary relationships within families of homologous genes or proteins, under the GNU GPL at


Release 10 of HOBACGEN (Homologous Bacterial Genes Database) is now available at

HOBACGEN is available through the Pôle Bio-Informatique Lyonnais, a web server supported by France’s Institute of Biology and Chemistry of Proteins and Laboratory of Biometry and Evolutionary Biology.

The database contains protein sequences of bacteria organized into families. It is based on sequences of bacteria and yeast from SwissProt 40 and TrEMBL 19, with some annotation modifications. There are 260,025 available in the current release.

Filed under

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.